Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025

Developed by Ascentage Pharma, lisaftoclax is an orally available Bcl-2 inhibitor. Early data from the studies have demonstrated effects on hematologic malignancies and solid tumors. Lisaftoclax is ...
TipRanks on MSN

Ascentage Pharma’s Promising Study on Lisaftoclax for CLL/SLL: A Potential Game-Changer?

Ascentage Pharma Group International (($HK:6855)) announced an update on their ongoing clinical study. Study Overview: Ascentage Pharma Group ...
TipRanks on MSN

BeOne Medicines Advances CLL and SLL Treatment with Promising Phase 3 Study

BeOne Medicines (($ONC)) announced an update on their ongoing clinical study. BeOne Medicines (ONC) is conducting a Phase 3 study titled ‘A Phase ...
KTLA

Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica ...

BRUIN CLL-314 is the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve patients INDIANAPOLIS, July 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: ...
Monthly Prescribing Reference

Pirtobrutinib Improves PFS in Treatment-Naïve CLL/SLL Patients

Pirtobrutinib was associated with a statistically significant improvement in PFS compared with bendamustine plus rituximab therapy. Topline data were announced from a phase 3 trial evaluating ...
The American Journal of Managed Care

Statins May Improve Survival Among Patients With CLL/SLL Receiving Ibrutinib

Statin use in CLL/SLL patients treated with ibrutinib reduced cancer-related death risk by 61% and improved survival outcomes. The study found no significant increase in severe side effects with ...
The American Journal of Managed Care

First-Line Ibrutinib Effective in CLL/SLL With or Without Risk Factors

Ibrutinib shows similar real-world overall survival outcomes for high-risk and non-high-risk CLL/SLL patients, suggesting cytogenetic risk factors do not affect its efficacy. The study utilized a ...
Monthly Prescribing Reference

Pirtobrutinib Noninferior to Ibrutinib in Head-To-Head CLL/SLL Trial

Findings showed pirtobrutinib was noninferior to ibrutinib in both the pre-treated and intent-to-treat populations for the endpoint of ORR. Topline data were announced from a head-to-head phase 3 ...
Morningstar

Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with ...

In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine ...
WebMD

Treating Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Copiktra

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...
Medscape

FDA Approves Pirtobrutinib for Previously Treated CLL/SLL

The US Food and Drug Administration (FDA) has granted accelerated approval to pirtobrutinib (Jaypirca; Eli Lilly and Company) for third-line or later treatment in adults with chronic lymphocytic ...
Seeking Alpha

Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica ...

Pirtobrutinib met the primary endpoint of response rate non-inferiority, favoring pirtobrutinib with a nominal P-value for superiority < 0.05 Progression-free survival data was immature, but trending ...